Understanding how a specific gene affects brain cell development in Alzheimer's disease
Official title: Investigation into transcriptomic control of dentate granule cell maturation and hyperexcitability in the apoE4 Alzheimer's Disease model
Funded at J. David Gladstone Institutes · NIH-10995282 · Data updated 2026-11-12
This study is looking at how a specific gene called apoE4 affects brain cells that help with memory, especially in people with Alzheimer's disease, to better understand early changes in the brain that might lead to memory problems.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $76,756 |
| NIH project number | 5F32AG085961-02 |
| Project ID | NIH-10995282 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who carry the apoE4 gene and are at risk for developing Alzheimer's disease.
✕Less likely to help
Patients without the apoE4 gene or those who are already diagnosed with advanced Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates the role of the apoE4 gene in the maturation and hyperactivity of brain cells involved in memory, specifically in the context of Alzheimer's disease. By studying both human and mouse models, the researchers aim to understand how apoE4 influences the development of dentate granule cells, which are crucial for memory function. The approach includes advanced techniques like single-nucleus RNA sequencing to analyze gene expression in these cells. The findings could provide insights into early changes in the brain that lead to cognitive decline in Alzheimer's patients.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating cognitive decline in individuals at risk for Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results in understanding the role of genetic factors in Alzheimer's disease, suggesting that this approach could yield valuable insights.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Tabuena, Dennis R — J. David Gladstone Institutes
- Study coordinator: Tabuena, Dennis R
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.